Issue Date: June 14, 2004
Abbott, Icos in drug pacts
Two antibody development deals were struck last week. In one, Abbott Laboratories will gain access to Protein Design Labs' technology for antibody humanization. Abbott is already a comarketer with MedImmune of the respiratory disease drug Synagis, a humanized antibody that was developed with PDL technology. Separately, Icos has licensed five monoclonal antibody candidates from Raven Biotechnologies. Abbott and Icos will make undisclosed payments to their partners.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society